Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Despite the well-documented association between insulin resistance and cardiovascular disease, the key targets of insulin relevant to the development of cardiovascular disease are not known. Here, using non-biased profiling methods, we identify the enzyme flavin-containing monooxygenase 3 ( Fmo3 ) to be a target of insulin. FMO3 produces trimethylamine N-oxide (TMAO), which has recently been suggested to promote atherosclerosis in mice and humans. We show that FMO3 is suppressed by insulin in vitro , increased in obese/insulin resistant male mice and increased in obese/insulin-resistant humans. Knockdown of FMO3 in insulin-resistant mice suppresses FoxO1, a central node for metabolic control, and entirely prevents the development of hyperglycaemia, hyperlipidemia and atherosclerosis. Taken together, these data indicate that FMO3 is required for FoxO1 expression and the development of metabolic dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insights into the mechanisms through which the meta-organismal pathway responsible for TMAO production are associated with enhanced CVD risks have thus far focused on the involvement of TMAO and FMO3 in atherosclerotic plaque development, altered sterol and glucose metabolism, and changes in macrophage phenotype (Wang et al., 2011 ; Koeth et al., 2013; Miao et al., 2015 ; Shih et al., 2015; War”
From Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk (2016) · cites this paper as Miao et al., 2015
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Knockdown of FMO3 in LIRKO mice suppressed FoxO1 expression (and improved glucose tolerance) by upregulating sterol regulatory element binding protein 2 (SREBP2) (77).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [77]
In the citing paper
“suppression of the host enzyme, FMO3, through antisense oligonucleotide-based approach, results in reduction of both circulating TMAO levels and diet-enhanced atherosclerosis in animal models”
From Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis (2015) · cites this paper as Miao et al., 2015
In the citing paper
“Taken together, these data suggest that FMO3, which is differentially regulated in male and female mice, is necessary but apparently not sufficient for the development of the diabetic phenotype.”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [76]
In the citing paper
“downregulation or knock-out of FMO3 leads to decreased levels of TMAO and it is athero-protective in these models, whereas increased expression of FMO3 leads to pro-atherogenic lipid profiles (e.g., higher VLDL and LDL) [75,76].”
From Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target (2018) · cites this paper as [76]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
affy—analysis of Affymetrix GeneChip data at the probe level
Gautier, L., Cope, L., Bolstad, B. M., & Irizarry, R. A. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg405 · Cited by 5,218
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis
Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., Sheehy, B. T., Britt, E. B., Fu, X., Wu, Y., Li, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3145 · Cited by 4,386
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
The Metabolic Syndrome: Time for a Critical Appraisal
Kahn, R., Buse, J., Ferrannini, E., & Stern, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2289 · Cited by 2,378
Research works printed but not linked: 2
- Shih, D. M. et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res 56, 22–37 (2015) . · DOI · Paper page
- Roberts, L. D., Souza, A. L., Gerszten, R. E. & Clish, C. B. Curr. Protoc. Mol. Biol eds Frederick M. A.et al. Chapter 30, Unit 30 32 31-24 (2012) .
Cited by
Plovier, H., Everard, A., Druart, C., Depommier, C., Van Hul, M., Geurts, L., Chilloux, J., Ottman, N., Duparc, T., Lichtenstein, L., et al. (2017) · Nature Medicine · doi:10.1038/nm.4236 · Cited by 2,204
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Zhu, W., Gregory, J. C., Org, E., Buffa, J. A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.011 · Cited by 1,968
“, 2013), further confirm the involvement of this metaorganismal pathway in both atherosclerosis development and regulation of whole body cholesterol and sterol metabolism (Miao et al., 2015; Shih et al., 2015; Warrier et al., 2015).”
InfluentialRole of gut microbiota in type 2 diabetes pathophysiology
Gurung, M., Li, Z., You, H., Rodrigues, R., Jump, D. B., Morgun, A., & Shulzhenko, N. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.051 · Cited by 1,708
“Akkermansia muciniphila and Lactobacillus plantarum reduce the expression of hepatic flavin monooxygenase 3 (Fmo3) [37,93], a key enzyme of xenobiotic metabolism, whose knockdown has been found to prevent development of hyperglycemia and hyperlipidemia in insulin resistant mice [110].”
BackgroundWang, Z., Roberts, A. B., Buffa, J. A., Levison, B. S., Zhu, W., Org, E., Gu, X., Huang, Y., Zamanian-Daryoush, M., Culley, M. K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.055 · Cited by 1,317
“Toward that end, recent studies confirm that suppression of the host enzyme, FMO3, through an antisense oligonucleotide-based approach, results in the reduction of both circulating TMAO levels and diet-enhanced atherosclerosis in animal models (Miao et al., 2015; Shih et al., 2015).”
BackgroundDietary lipids, gut microbiota and lipid metabolism
Schoeler, M., & Caesar, R. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09512-0 · Cited by 1,163
Role of gut microbiota in atherosclerosis
Jonsson, A. L., & Bäckhed, F. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.183 · Cited by 644
Janeiro, M., Ramírez, M., Milagro, F., Martínez, J., & Solas, M. (2018) · Nutrients · doi:10.3390/nu10101398 · Cited by 631
Schiattarella, G. G., Sannino, A., Toscano, E., Giugliano, G., Gargiulo, G., Franzone, A., Trimarco, B., Esposito, G., & Perrino, C. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx342 · Cited by 563
Li, X. S., Obeid, S., Klingenberg, R., Gencer, B., Mach, F., Räber, L., Windecker, S., Rodondi, N., Nanchen, D., Muller, O., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehw582 · Cited by 479
Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease
Zeisel, S. H., & Warrier, M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064732 · Cited by 475
“Knockdown of FMO3 in LIRKO mice suppressed FoxO1 expression (and improved glucose tolerance) by upregulating sterol regulatory element binding protein 2 (SREBP2) (77).”
BackgroundInfluentialMicrobial modulation of cardiovascular disease
Brown, J. M., & Hazen, S. L. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.149 · Cited by 440
Trimethylamine N-Oxide Binds and Activates PERK to Promote Metabolic Dysfunction
Chen, S., Henderson, A., Petriello, M. C., Romano, K. A., Gearing, M., Miao, J., Schell, M., Sandoval-Espinola, W. J., Tao, J., Sha, B., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.021 · Cited by 427
Self-citationRole of the gut microbiota in type 2 diabetes and related diseases
Yang, G., Wei, J., Liu, P., Zhang, Q., Tian, Y., Hou, G., Meng, L., Xin, Y., & Jiang, X. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154712 · Cited by 418
Trace Amines and Their Receptors
Gainetdinov, R. R., Hoener, M. C., & Berry, M. D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015305 · Cited by 384
“As previously indicated, there is a growing body of work that implicates the trimethylamine metabolite TMAO in cardiovascular disease (Koeth et al., 2013;Miao et al., 2015).”
BackgroundOrgan, C. L., Otsuka, H., Bhushan, S., Wang, Z., Bradley, J., Trivedi, R., Polhemus, D. J., Tang, W. H. W., Wu, Y., Hazen, S. L., et al. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002314 · Cited by 382
Yang, S., Li, X., Yang, F., Zhao, R., Pan, X., Liang, J., Tian, L., Li, X., Liu, L., Xing, Y., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01360 · Cited by 345
“Koeth, R. A., Wang, Z., Levison, B. S., Buffa, J. A., Org, E., and Sheehy, B. T. (2013). Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.”
Fennema, D., Phillips, I. R., & Shephard, E. A. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.070615 · Cited by 355
“FMO3 has also been identified as a target of insulin (Miao et al., 2015): Fmo3 expression was more than 1000-fold higher in the livers of male liver insulin receptor-knockout (LIRKO) mice compared with littermate controls, whereas knockdown of FMO3 in LIRKO mice reduced expression of the…”
Backgroundl-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans
Koeth, R. A., Lam-Galvez, B. R., Kirsop, J., Wang, Z., Levison, B. S., Gu, X., Copeland, M. F., Bartlett, D., Cody, D. B., Dai, H. J., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94601 · Cited by 327
“Importantly, recent studies aimed at blocking the metaorganismal TMAO pathway through multiple approaches have confirmed the inhibition of diet-dependent atherosclerosis in animal models, either by targeting the initial microbial formation of TMA from choline through use of a nonlethal small-molecule inhibitor (19), o…”
Relationship of Serum Trimethylamine N-Oxide (TMAO) Levels with early Atherosclerosis in Humans
Randrianarisoa, E., Lehn-Stefan, A., Wang, X., Hoene, M., Peter, A., Heinzmann, S. S., Zhao, X., Königsrainer, I., Königsrainer, A., Balletshofer, B., et al. (2016) · Scientific Reports · doi:10.1038/srep26745 · Cited by 296
Schugar, R. C., Shih, D. M., Warrier, M., Helsley, R. N., Burrows, A., Ferguson, D., Brown, A. L., Gromovsky, A. D., Heine, M., Chatterjee, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.077 · Cited by 291
“Using ametabolomics platform, Miao and colleagues recently showed that mice with selective hepatic insulin resistance (liver insulin receptor knockout mice [LIRKO]) have elevated levels of circulating TMAO and a profound upregulation of the TMAO-producing enzyme FMO3 in the liver (Miao et al., 2015).”
InfluentialSelf-citationEvaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans
Meijnikman, A. S., Gerdes, V. E., Nieuwdorp, M., & Herrema, H. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00192 · Cited by 278
Inter-organ cross-talk in metabolic syndrome
Priest, C., & Tontonoz, P. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0145-5 · Cited by 279
Senthong, V., Wang, Z., Li, X. S., Fan, Y., Wu, Y., Wilson Tang, W. H., & Hazen, S. L. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002816 · Cited by 270
Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome
Barrea, L., Annunziata, G., Muscogiuri, G., Di Somma, C., Laudisio, D., Maisto, M., De Alteriis, G., Tenore, G. C., Colao, A., & Savastano, S. (2018) · Nutrients · doi:10.3390/nu10121971 · Cited by 257
“[45] found that liver insulin receptor knockout mice, characterized by a selective hepatic insulin resistance, have increased circulating TMAO levels associated with a strong up-regulation of the TMAO-producing enzyme FMO3 in the liver [45].”
BackgroundSmits, L. P., Kootte, R. S., Levin, E., Prodan, A., Fuentes, S., Zoetendal, E. G., Wang, Z., Levison, B. S., Cleophas, M. C. P., Kemper, E. M., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.008342 · Cited by 251
Senthong, V., Li, X. S., Hudec, T., Coughlin, J., Wu, Y., Levison, B., Wang, Z., Hazen, S. L., & Tang, W. H. W. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.546 · Cited by 242
“It is also of interest that recent studies have further implicated flavin monooxygenase 3 in atherosclerosis development in rodent models of diabetes (39).”
BackgroundDuttaroy, A. K. (2021) · Nutrients · doi:10.3390/nu13010144 · Cited by 223
Liu, Y., & Dai, M. (2020) · Mediators of Inflammation · doi:10.1155/2020/4634172 · Cited by 224
Nesci, A., Carnuccio, C., Ruggieri, V., D’Alessandro, A., Di Giorgio, A., Santoro, L., Gasbarrini, A., Santoliquido, A., & Ponziani, F. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109087 · Cited by 208
Tang, W. H. W., Wang, Z., Li, X. S., Fan, Y., Li, D. S., Wu, Y., & Hazen, S. L. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.263640 · Cited by 231
“Interestingly, recent animal model studies using the liver specific insulin receptor null mouse in the low-density lipoprotein (LDL) receptor null background, an insulin resistance mouse model of atherosclerosis, showed that suppression of hepatic flavin monooxygenase 3 and TMAO levels inhibited both hyperglycemia and…”
BackgroundThe Role of Gut Microbiota in Atherosclerosis and Hypertension
Ma, J., & Li, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01082 · Cited by 224
Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis
Li, Z., Wu, Z., Yan, J., Liu, H., Liu, Q., Deng, Y., Ou, C., & Chen, M. (2019) · Laboratory Investigation · doi:10.1038/s41374-018-0091-y · Cited by 216
Trimethylamine- N -Oxide: Friend, Foe, or Simply Caught in the Cross-Fire?
Cho, C. E., & Caudill, M. A. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.005 · Cited by 218
Role of gut microbiota in cardiovascular diseases
Novakovic, M., Rout, A., Kingsley, T., Kirchoff, R., Singh, A., Verma, V., Kant, R., & Chaudhary, R. (2020) · World Journal of Cardiology · doi:10.4330/wjc.v12.i4.110 · Cited by 202
Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes
Shan, Z., Sun, T., Huang, H., Chen, S., Chen, L., Luo, C., Yang, W., Yang, X., Yao, P., Cheng, J., et al. (2017) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.117.157107 · Cited by 210
Al-Obaide, M., Singh, R., Datta, P., Rewers-Felkins, K., Salguero, M., Al-Obaidi, I., Kottapalli, K., & Vasylyeva, T. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6090086 · Cited by 194
Canyelles, M., Tondo, M., Cedó, L., Farràs, M., Escolà-Gil, J. C., & Blanco-Vaca, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103228 · Cited by 188
Skye, S. M., Zhu, W., Romano, K. A., Guo, C.-J., Wang, Z., Jia, X., Kirsop, J., Haag, B., Lang, J. M., DiDonato, J. A., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.313142 · Cited by 189
Gut microbiome and its role in cardiovascular diseases
Ahmadmehrabi, S., & Tang, W. H. W. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000445 · Cited by 185
The gut microbiota as a novel regulator of cardiovascular function and disease
Battson, M. L., Lee, D. M., Weir, T. L., & Gentile, C. L. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.12.010 · Cited by 183
Zhuang, R., Ge, X., Han, L., Yu, P., Gong, X., Meng, Q., Zhang, Y., Fan, H., Zheng, L., Liu, Z., et al. (2019) · Obesity Reviews · doi:10.1111/obr.12843 · Cited by 179
“Insulin resistance and the corresponding upregulation of insulin levels contributed to FMO3 activity and the increase in TMAO levels.(50) Inhibition of FMO3, which can reduce TMAO amounts, decreased the plasma glucose in murine models.”
BackgroundGut microbiome, endocrine control of gut barrier function and metabolic diseases
Régnier, M., Van Hul, M., Knauf, C., & Cani, P. D. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0473 · Cited by 179
Interaction between gut microbiome and cardiovascular disease
Peng, J., Xiao, X., Hu, M., & Zhang, X. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.10.063 · Cited by 174
Kim, R. B., Morse, B. L., Djurdjev, O., Tang, M., Muirhead, N., Barrett, B., Holmes, D. T., Madore, F., Clase, C. M., Rigatto, C., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.01.014 · Cited by 179
Heianza, Y., Sun, D., Li, X., DiDonato, J. A., Bray, G. A., Sacks, F. M., & Qi, L. (2019) · Gut · doi:10.1136/gutjnl-2018-316155 · Cited by 177
Fu, B. C., Hullar, M. A., Randolph, T. W., Franke, A. A., Monroe, K. R., Cheng, I., Wilkens, L. R., Shepherd, J. A., Madeleine, M. M., Le Marchand, L., et al. (2020) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqaa015 · Cited by 172
Gut Microbiota and Ischemic Stroke: The Role of Trimethylamine N-Oxide
Nam, H. S. (2019) · Journal of Stroke · doi:10.5853/jos.2019.00472 · Cited by 176
Trimethylamine N ‐Oxide and Mortality Risk in Patients With Peripheral Artery Disease
Senthong, V., Wang, Z., Fan, Y., Wu, Y., Hazen, S. L., & Tang, W. H. W. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004237 · Cited by 175
“In several recent studies genetically repressing hepatic flavin monooxygenase 3 expression, the host enzyme primarily responsible for converting gut microbe–generated TMA into TMAO, choline diet–enhanced atherosclerosis was inhibited, further implicating the TMAO pathway in atherosclerosis development.(18,19) These an…”
BackgroundTrimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease
Roncal, C., Martínez-Aguilar, E., Orbe, J., Ravassa, S., Fernandez-Montero, A., Saenz-Pipaon, G., Ugarte, A., Estella-Hermoso de Mendoza, A., Rodriguez, J. A., Fernández-Alonso, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52082-z · Cited by 158
Zhu, W., Buffa, J. A., Wang, Z., Warrier, M., Schugar, R., Shih, D. M., Gupta, N., Gregory, J. C., Org, E., Fu, X., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14234 · Cited by 161
Long-Term Changes in Gut Microbial Metabolite Trimethylamine N-Oxide and Coronary Heart Disease Risk
Heianza, Y., Ma, W., DiDonato, J. A., Sun, Q., Rimm, E. B., Hu, F. B., Rexrode, K. M., Manson, J. E., & Qi, L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.060 · Cited by 158
“Our observations are supported by previous findings from experimental studies such as that modulation of the TMAO-generating enzyme FMO3 impacts systemic TMAO levels (38), and the FMO3 is involved in atherosclerotic pathogenesis by regulating cholesterol metabolism and insulin resistance (39,40).”
ResultMicrobiome, trimethylamine N-oxide, and cardiometabolic disease
Tang, W. H. W., & Hazen, S. L. (2017) · Translational Research · doi:10.1016/j.trsl.2016.07.007 · Cited by 160
Trimethylamine N-Oxide in Relation to Cardiometabolic Health—Cause or Effect?
Papandreou, C., Moré, M., & Bellamine, A. (2020) · Nutrients · doi:10.3390/nu12051330 · Cited by 146
“Knockdown of FMO3 in insulin-resistant mice prevented the development of hyperglycemia, hyperlipidemia and atherosclerosis [117], and reduced TMAO levels from 7 μM to 2.”
BackgroundTrimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction
Suzuki, T., Heaney, L. M., Jones, D. J. L., & Ng, L. L. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.264853 · Cited by 146
EPRS is a critical mTORC1–S6K1 effector that influences adiposity in mice
Arif, A., Terenzi, F., Potdar, A. A., Jia, J., Sacks, J., China, A., Halawani, D., Vasu, K., Li, X., Brown, J. M., et al. (2017) · Nature · doi:10.1038/nature21380 · Cited by 128
Probiotic mechanisms of action
Halloran, K., & Underwood, M. A. (2019) · Early Human Development · doi:10.1016/j.earlhumdev.2019.05.010 · Cited by 117
Witkowski, M., Witkowski, M., Friebel, J., Buffa, J. A., Li, X. S., Wang, Z., Sangwan, N., Li, L., DiDonato, J. A., Tizian, C., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab263 · Cited by 126
Dumas, M.-E., Rothwell, A. R., Hoyles, L., Aranias, T., Chilloux, J., Calderari, S., Noll, E. M., Péan, N., Boulangé, C. L., Blancher, C., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.039 · Cited by 114
Krüger, R., Merz, B., Rist, M. J., Ferrario, P. G., Bub, A., Kulling, S. E., & Watzl, B. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700363 · Cited by 119
“[69] reporting high FMO3activity and therefore indirect TMAO as relevant regarding CVD risk, rather than high levels of direct TMAO from fish.”
Simó, C., & García‐Cañas, V. (2020) · Food & Function · doi:10.1039/d0fo01237h · Cited by 122
Gut-Microbial Metabolites, Probiotics and Their Roles in Type 2 Diabetes
Zhai, L., Wu, J., Lam, Y. Y., Kwan, H. Y., Bian, Z., & Wong, H. L. X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312846 · Cited by 119
Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy
Wang, B., Qiu, J., Lian, J., Yang, X., & Zhou, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.723886 · Cited by 122
Brown, J. M., & Hazen, S. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.765388 · Cited by 108
Current and future perspectives of functional metabolomics in disease studies–A review
Yan, M., & Xu, G. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.04.006 · Cited by 105
Bergeron, N., Williams, P. T., Lamendella, R., Faghihnia, N., Grube, A., Li, X., Wang, Z., Knight, R., Jansson, J. K., Hazen, S. L., et al. (2016) · British Journal of Nutrition · doi:10.1017/s0007114516004165 · Cited by 100
“Moreover, in two different mouse models of atherosclerosis, anti-sense oligonucleotide targeting of hepatic flavin monooxygenase 3 has been shown to similarly inhibit TMAO formation and development of atherosclerosis((34,35)).”
BackgroundMafune, A., Iwamoto, T., Tsutsumi, Y., Nakashima, A., Yamamoto, I., Yokoyama, K., Yokoo, T., & Urashima, M. (2016) · Clinical and Experimental Nephrology · doi:10.1007/s10157-015-1207-y · Cited by 103
“can prevent the development of hyperglycemia and atherosclerosis in a diabetes mouse model [19], suggesting that the FMO3/TMAO pathway may play an important role in the pathophysiology of diabetes.”
BackgroundHigh Mobility Group Box 1 Mediates TMAO-Induced Endothelial Dysfunction
Singh, G. B., Zhang, Y., Boini, K. M., & Koka, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143570 · Cited by 99
Gut Microbiota and Atherosclerosis—Focusing on the Plaque Stability
Shen, X., Li, L., Sun, Z., Zang, G., Zhang, L., Shao, C., & Wang, Z. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.668532 · Cited by 110
“Some studies have demonstrated that knockdown of the FMO3 gene can significantly reduce the production of TMAO (67, 68).”
BackgroundShanmugham, M., Bellanger, S., & Leo, C. H. (2023) · Pharmaceuticals · doi:10.3390/ph16040504 · Cited by 112
Trimethylamine N-oxide impairs β-cell function and glucose tolerance
Kong, L., Zhao, Q., Jiang, X., Hu, J., Jiang, Q., Li, S., Peng, X., Wang, S., Chen, Y., Wan, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46829-0 · Cited by 110
“In the livers of streptozotocin (STZ)-treated mice and ob/ob mice, Fmo3 mRNA and protein expression were markedly induced 18 .”
Gut microbiota and microbiota-derived metabolites in cardiovascular diseases
Chen, X., Zhang, H., Ren, S., Ding, Y.-N., Remex, N. S., Bhuiyan, M. S., Qu, J.-H., & Tang, X. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002206 · Cited by 112
“For example, the knockdown of FMO3, an important enzyme responsible for TMAO production, prevented the progression of atherosclerosis in mice.([160]) The administration of DMB in drinking water, an inhibitor of microbial TMA lyases, was reported to repress TMA production and circulating TMAO levels in mice fed choline…”
BackgroundRole of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9
Miao, J., Manthena, P. V., Haas, M. E., Ling, A. V., Shin, D.-J., Graham, M. J., Crooke, R. M., Liu, J., & Biddinger, S. B. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305688 · Cited by 93
Self-citationGut and obesity/metabolic disease: Focus on microbiota metabolites
Lin, K., Zhu, L., & Yang, L. (2022) · MedComm · doi:10.1002/mco2.171 · Cited by 92
The Impact of the Adipose Organ Plasticity on Inflammation and Cancer Progression
Corrêa, L. H., Cardoso, G. S. H. R., & Magalhães, K. G. (2019) · Cells · doi:10.3390/cells8070662 · Cited by 109
“As the end product of metabolism, circulating TMAO is indicative of cardiovascular disease [76].”
BackgroundTsai, C.-Y., Lu, H.-C., Chou, Y.-H., Liu, P.-Y., Chen, H.-Y., Huang, M.-C., Lin, C.-H., & Tsai, C.-N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.814770 · Cited by 92
“Trimethylamine N-oxide is closely linked to cardiometabolic diseases, including atherosclerosis and T2D (54).”
BackgroundGut bacterial phospholipase Ds support disease-associated metabolism by generating choline
Chittim, C. L., Campo, A. M.-D., & Balskus, E. P. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0294-4 · Cited by 108
From role of gut microbiota to microbial-based therapies in type 2-diabetes
Ebrahimzadeh Leylabadlo, H., Sanaie, S., Sadeghpour Heravi, F., Ahmadian, Z., & Ghotaslou, R. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104268 · Cited by 92
Zhou, Y., Zhang, Y., Jin, S., Lv, J., Li, M., & Feng, N. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117031 · Cited by 101
The complex metabolism of trimethylamine in humans: endogenous and exogenous sources
Chhibber-Goel, J., Gaur, A., Singhal, V., Parakh, N., Bhargava, B., & Sharma, A. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2016.6 · Cited by 93
Busnelli, M., Manzini, S., & Chiesa, G. (2019) · Nutrients · doi:10.3390/nu12010079 · Cited by 98
Ancestral-sequence reconstruction unveils the structural basis of function in mammalian FMOs
Nicoll, C. R., Bailleul, G., Fiorentini, F., Mascotti, M. L., Fraaije, M. W., & Mattevi, A. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0347-2 · Cited by 93
Pathak, P., Helsley, R. N., Brown, A. L., Buffa, J. A., Choucair, I., Nemet, I., Gogonea, C. B., Gogonea, V., Wang, Z., Garcia-Garcia, J. C., et al. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00584.2019 · Cited by 86
Trøseid, M., Hov, J. R., Nestvold, T. K., Thoresen, H., Berge, R. K., Svardal, A., & Lappegård, K. T. (2016) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.0120 · Cited by 84
Regulated methionine oxidation by monooxygenases
Manta, B., & Gladyshev, V. N. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.02.010 · Cited by 79
Flavin-containing monooxygenases in aging and disease: Emerging roles for ancient enzymes
Rossner, R., Kaeberlein, M. R., & Leiser, S. F. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.779678 · Cited by 93
“Estrogen (29) and insulin (34) activate FMO transcription, whereas testosterone (29) and glucagon (37) are repressors of FMO transcription, but FMO5 is again an exception (38).”
BackgroundHeianza, Y., Sun, D., Smith, S. R., Bray, G. A., Sacks, F. M., & Qi, L. (2018) · Diabetes Care · doi:10.2337/dc17-2108 · Cited by 80
Plasma concentration of trimethylamine-N-oxide and risk of gestational diabetes mellitus
Li, P., Zhong, C., Li, S., Sun, T., Huang, H., Chen, X., Zhu, Y., Hu, X., Peng, X., Zhang, X., et al. (2018) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy116 · Cited by 76
Trimethylamine N -oxide: heart of the microbiota–CVD nexus?
Naghipour, S., Cox, A. J., Peart, J. N., Toit, E. F. D., & Headrick, J. P. (2020) · Nutrition Research Reviews · doi:10.1017/s0954422420000177 · Cited by 86
“Whether FMO3-dependent elevations in TMAO might contribute to diabetes remains to be established, though FMO3 knockdown reduces hyperglycaemia in a murine model of hepatic insulin resistance(55), and circulating TMAO is predictive of insulin resistancewith obesogenic feeding in macaques(81).”
BackgroundInfluentialGao, J., Yan, K.-T., Wang, J.-X., Dou, J., Wang, J., Ren, M., Ma, J., Zhang, X., & Liu, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-59235-5 · Cited by 80
Fu, Q., Zhao, M., Wang, D., Hu, H., Guo, C., Chen, W., Li, Q., Zheng, L., & Chen, B. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.07.071 · Cited by 76
Schugar, R. C., Gliniak, C. M., Osborn, L. J., Massey, W. J., Sangwan, N., Horak, A. J., Banerjee, R., Orabi, D., Helsley, R. N., Brown, A. L., et al. (2022) · eLife · doi:10.7554/elife.63998 · Cited by 78
A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO)
Barrea, L., Muscogiuri, G., Annunziata, G., Laudisio, D., de Alteriis, G., Tenore, G. C., Colao, A., & Savastano, S. (2019) · Nutrients · doi:10.3390/nu11061310 · Cited by 73
“[10,53] found that an animal model characterized by a selective hepatic insulin resistance has increased circulating TMAO levels associated with the up-regulation of the TMAO-producing enzyme FMO3 in the liver.”
BackgroundIlyas, A., Wijayasinghe, Y. S., Khan, I., Samaloty, N. M. E., Adnan, M., Dar, T. A., Poddar, N. K., Singh, L. R., Sharma, H., & Khan, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.964624 · Cited by 76
“Knockdown of FMO3 was demonstrated to suppress FoxO1 and improve glucose tolerance in mice (Miao et al., 2015).”
BackgroundFarhangi, M. A., Vajdi, M., & Asghari-Jafarabadi, M. (2020) · Nutrition Journal · doi:10.1186/s12937-020-00592-2 · Cited by 72
“The investigators propose that the suppression of TMA creation or reducing plasma levels of TMAO can serve as a way of inhibiting diet induced atherosclerosis [61, 62].”
BackgroundPhillips, I. R., & Shephard, E. A. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1643515 · Cited by 76
Relationship between elevated plasma trimethylamine N-oxide levels and increased stroke injury
Wu, C., Xue, F., Lian, Y., Zhang, J., Wu, D., Xie, N., Chang, W., Chen, F., Wang, L., Wei, W., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000008862 · Cited by 76
Lemaître, R. N., Jensen, P. N., Wang, Z., Fretts, A. M., McKnight, B., Nemet, I., Biggs, M. L., Sotoodehnia, N., Otto, M. C. D. O., Psaty, B. M., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.22844 · Cited by 74
Biocatalytic Characterization of Human FMO5: Unearthing Baeyer–Villiger Reactions in Humans
Fiorentini, F., Geier, M., Binda, C., Winkler, M., Faber, K., Hall, M., & Mattevi, A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01016 · Cited by 69
Shih, D. M., Zhu, W., Schugar, R. C., Meng, Y., Jia, X., Miikeda, A., Wang, Z., Zieger, M., Lee, R., Graham, M., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312592 · Cited by 67
Self-citationIntestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease
Hui, D. Y. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000334 · Cited by 67
Metadata
- Authors
- Miao, J., Ling, A. V., Manthena, P. V., Gearing, M. E., Graham, M. J., Crooke, R. M., Croce, K. J., Esquejo, R. M., Clish, C. B., Morbid Obesity Study Group, Torrecilla, E., Vázquez, G. F., Rubio, M. A., Cabrerizo, L., Barabash, A., Pernaute, A. S., Torres, A. J., Vicent, D., & Biddinger, S. B.
- Affiliations
- Boston Children's Hospital (US)
- Ionis Pharmaceuticals (United States) (US)
- Brigham and Women's Hospital (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Broad Institute (US)
- Carlos III Hospital (ES)
- Hospital Clínico San Carlos (ES)
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Biddinger, Sudha B.
- ORCID
- Venue
- Nature Communications
- Published
- 2015-04-07
- Volume
- 6
- Issue
- 1
- Pages
- 6498-6498
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4391288
- OpenAlex
- W2094278898
- Cited by
- 368
- References
- 58
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 26 · 2023: 35 · 2022: 41 · 2021: 40 · 2020: 44 · 2019: 30 · 2018: 33 · 2017: 29 · 2016: 35 · 2015: 9
- FWCI
- 30.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- American Heart Association
- Brigham and Women's Hospital
- Wake Forest University
- Broad Institute
- Institut National de la Santé et de la Recherche Médicale
- Sociedad de Endocrinología, Nutrición y Diabetes de la Comunidad de Madrid
- National Heart, Lung, and Blood Institute (R01HL048044, HL48044, HL109650, R01HL109650)
- National Institute of Diabetes and Digestive and Kidney Diseases (L40 DK065607, K99DK100539, DK-100539, R00DK100539)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- FMO3, insulin resistance, diabetes-associated atherosclerosis, trimethylamine N-oxide, FOXO1, obesity, hyperglycemia, hyperlipidemia, metabolic dysfunction, insulin signaling
- MeSH terms
- Forkhead Box Protein O1, Animals, Diabetes Mellitus, Type 2, Humans, Hyperglycemia, Hyperlipidemias, Hypoglycemic Agents, Insulin, Insulin Resistance, Cholesterol, HDL, Cholesterol, LDL, Liver, Male, Obesity, Oxygenases, RNA, Messenger, Triglycerides, Blotting, Western, Rats, Sprague-Dawley, Gene Expression Profiling, Hepatocytes, Atherosclerosis, Mice, Rats, Forkhead Transcription Factors, Gene Knockdown Techniques, Real-Time Polymerase Chain Reaction, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.